NCT05507541: TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 2 | 41 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Blood Sample Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Computerized axial tomography (procedure), Ontorpacept, SIRPa-Fc Fusion Protein TTI-621, SIRPaFc, TTI 621, TTI-621, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Positron emission tomography (procedure), Maplirpacept, SIRPa-IgG4 Fc, SIRPa-IgG4 Fc TTI-622, TTI 622, TTI-622, TTI622, SIRPa-IgG4-Fc Fusion Protein TTI-622, Biopsy, BIOPSY_TYPE, Bx | Mayo Clinic | Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory ALK Positive Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Gray Zone Lymphoma | 11/26 | 11/27 | | |
